Janssen has acquired an NS5a replication complex inhibitor that will be evaluated with Simeprevir in future clinical development
Stockholm, Sweden — Medivir AB (OMX: MVIR) announced that Janssen Pharmaceuticals, Inc. (Janssen) has acquired the investigational compound GSK2336805 (GSK805), an NS5a replication complex inhibitor in phase II development for the treatment of chronic hepatitis C. Janssen has acquired all rights to develop and commercialize GSK2336805 including in combination with other drugs. Janssen acquired the compound from an affiliate of GlaxoSmithKline plc, financial details of the agreement have not been disclosed. Janssen plans to initiate phase II studies to evaluate the use of GSK805 in